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Abstract.
Background: Despite optimal dopaminergic treatment most patients in moderate to advanced stages of Parkinson’s disease
(PD) experience progressively increasing disabilities, necessitating a shift from oral medication to device-aided thera-
pies, including deep brain stimulation (DBS), intrajejunal levodopa-carbidopa infusion (IJLI), and continuous subcutaneous
apomorphine infusion (CSAI). However, these therapies are costly, limiting their implementation.
Objectives: To perform a systematic review on cost-effectiveness analyses for device-aided therapies in PD.
Methods: References were identified by performing a systematic search in the PubMed and Web of Science databases in
accordance with the PRISMA statement. In the absence of universal cost-effectiveness definitions, the gross domestic product
per capita (GDP) in the country where a study was performed was used as a cut-off for cost-effectiveness based on cost per
quality adjusted life year (QALY) gained.
Results: In total 30 studies were retrieved. All device-aided therapies improved quality of life compared to best medical
treatment, with improvements in QALYs between 0.88 and 1.26 in the studies with long temporal horizons. For DBS, nearly
all studies showed that cost per QALY was below the GDP threshold. For infusion therapies only three studies showed a
cost per QALY below this threshold, with several studies with long temporal horizons showing costs below or near the GDP
threshold.
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Conclusion: Of the device-aided therapies, DBS can be considered cost-effective, but the majority of infusion therapy
studies showed that these were less cost-effective. However, long-term use of the infusion therapies appears to improve their
cost-effectiveness and in addition, several strategies are underway to reduce these high costs.
Keywords: Parkinson’s disease, cost-effectiveness, deep brain stimulation, quality adjusted life year, levodopa-carbidopa
intestinal gel, continuous subcutaneous apomorphine infusion
INTRODUCTION
Parkinson’s disease (PD) is a progressive neurode-
generative disease, mostly affecting older people,
with a clear impact on quality of life [1]. In the
early stages the disease can be managed well with
oral therapies at a relatively low cost, but as the dis-
ease progresses into more advanced stages, the effect
of these therapies diminishes and associated costs
of treatment increase. The impact on societal bur-
den of advanced PD may be considerable as the top
20% of patients incurring most costs, often those in
advanced stages of the disease, are responsible for
70% of secondary care costs associated with the dis-
ease (£16,500 (D 22,493) per patient per year in the
UK) [2]. As the incidence of PD is rising sharply, with
a continuous growth in prevalence that is expected to
double within the next 25 years [3], costs associated
with treatment and the burden this places on society
is becoming increasingly relevant.
Oral dopaminergic treatment is effective for alle-
viating the early symptoms of PD. However, despite
optimal dopaminergic treatment most patients in
moderate to advance stages of PD experience pro-
gressively increasing disabilities [4]. At this stage of
the disease motor fluctuations are almost inevitable
with levodopa treatment [5], and calls for the ini-
tiation of device-aided therapies once the criteria
for these therapies are met [6]. Moreover, motor
fluctuations are often accompanied by non-motor
fluctuations, adding to a separate complexity and the
decline in perceived quality of life [7]. When fluc-
tuations occur, treatment aims should shift from oral
medication to more continuous dopaminergic stim-
ulation in the form of device-aided therapies [8],
not in the least as these therapies also have a posi-
tive effect on many non-motor symptoms, and thus
improve quality of life for PD patients [9, 10]. Cur-
rently available device-aided therapies are deep brain
stimulation (DBS), intrajejunal Levodopa-carbidopa
infusion (IJLI) and continuous subcutaneous apomor-
phine infusion (CSAI).
DBS, of either the subthalamic nucleus (STN) or
globus pallidus internus (GPI), was approved by the
US Food and Drug Administration in 2002 as a treat-
ment option for PD, although the technique had been
in use since the 1980s [11]. Randomized clinical tri-
als have confirmed its effectiveness in improvement
of motor and non-motor symptoms as well as quality
of life in moderated and advanced stages of PD [9,
10, 12, 13]. Also for CSAI and IJLI numerous stud-
ies have shown that these two treatments are clinically
useful and efficacious in improving levodopa induced
dyskinesias and other motor complications of PD
[14]. In addition, all three device-aided treatments
have a differential effect on non-motor symptoms of
PD [9, 10]. Despite the clear effectiveness of device-
aided therapies in the management of both motor
and non-motor symptoms in advanced PD, concerns
continue to exist regarding the high costs associated
with these therapies. Here, economic evaluations are
useful to assess their cost-effectiveness, aiding in
decision-making of when to introduce these therapies
in PD patients, in addition to the choice of device-
aided therapy type.
Therefore, we aimed to perform a systematic re-
view of the available literature on economic analyses
of device-aided therapies in patients with PD. Addi-
tionally, we looked at ongoing efforts to reduce the
costs associated with these therapies.
METHODS
In this systematic review, we aimed to address the
following clinical questions:
1. What is the cost-effectiveness of CSAI treatment
in PD patients compared to best medical treatment
using oral formulations?
2. What is the cost-effectiveness of IJLI in PD
patients compared to best medical treatment using
oral formulations?
3. What is the cost-effectiveness of DBS in PD
patients compared to best medical treatment using
oral formulations?
4. What strategies are currently being undertaken to
reduce costs associated with device-aided thera-
pies?
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Table 1
Search queries
Database Query Number of records
PubMed parkinson’s disease[MeSH Terms] AND 248
(levodopa infusion OR apomorphine[MeSH Terms] OR
deep brain stimulation[MeSH Terms]) AND cost
References used in the current review were identi-
fied by performing a systematic search in the PubMed
and Web of Science databases in accordance with the
Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement [15]. The
search query was based on the PICO strategy and
included 1) Population: advanced PD; 2) Interven-
tion: CSAI, IJLI, or DBS; 3) Context/setting: all
countries; and 4) Outcomes: cost-effectiveness of
device-aided therapies. We determined time horizon
of the intervention of at least one year. The time
span of the search ranged from 1988 to April 2020.
For PubMed, we used the Medical Subject Heading
(MeSH) term “Parkinson’s disease” combined with
the terms “Apomorphine”, “Levodopa Infusion” or
“Deep Brain Stimulation”, and “Cost” (Table 1). All
MeSH terms were expanded to include all subhead-
ings to identify all relevant articles. All potentially
eligible manuscripts were considered regardless of
publication type or language. The final search was
performed in April 2020. In addition, reference lists
of identified articles were screened for further poten-
tially relevant papers. Articles were selected based on
the following eligibility criteria: (1) original research,
and (2) performed in PD patients. The search query
is shown in Table 1 and the study selection process is
shown in Fig. 1.
As universal guidelines on what is considered
cost-effective are lacking, and marked differences in
reimbursement policies exist between countries, we
decided to use the gross domestic product per capita
(GDP) as a threshold for cost-ineffectiveness [16].
The GDP of each country in the year in which a
study was performed was used to determine whether
Fig. 1. Study selection process.
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the device-aided therapy studied was cost-effective
(defined by a cost beneath the GDP of the respec-
tive country). Information on GDP was downloaded
from the Organisation for Economic Co-operation
and Development [17]. All costs not provided in euro
were converted to euro based on the average exchange
rate for the year (http://www.xe.com) in which the
analysis for each included manuscript was conducted.
In addition to the aforementioned aims we have
included manuscripts identifying implementation
barriers of device-aided therapies in PD. For this, arti-
cles were selected based on their relevance and these
were not included in the systematic search as this was
not the primary aim of this review.
RESULTS
An overview of cost-effectiveness for the respec-
tive device-aided therapies is provided in Table 2. In
total, 248 articles were retrieved from the database
search by the query. Based on the selection process,
30 articles were included (Fig. 1); 30 on cost-eff-
ectiveness analyses for the device-aided therapies
and a further three manuscripts on current efforts to
reduce costs in these therapies.
Cost-effectiveness
Intrajejunal levodopa infusion
To date, 10 studies have looked into the cost-eff-
ectiveness for IJLI in PD patients with cohorts rang-
ing from 10 to 354 patients [16, 18–26]. Eight studies
have performed a cost-effectiveness analysis (CEA),
of which one looked at costs per point UPDRS
improvement, and two studies did not perform a CEA.
A summary of the findings in the eight studies where
a CEA on IJLI costs was performed, is provided in
Table 2.
In general, in studies with the smallest sample size,
there was a tendency for IJLI, although beneficial for
quality of life and motor function, to be more exp-
ensive per Quality Adjusted Life Year (QALY) than
standard treatment [18, 23] (Table 2). On the other
hand, Kamusheva et al. [16] found that IJLI was cost-
effective for PD patients with prolonged akinesia.
Here, it was observed that the additional annual cost
was 1903.56 BGN (D 971.01) for patients treated with
IJLI, far below the recommended threshold of annual
GDP per capita of Bulgaria (Table 2). In the UK, Lo-
win et al. showed that IJLI treatment was associated
with an incremental cost per QALY of £36,024
(D 41,407) [22], slightly above the GDP threshold of
the UK in 2011 when this study was published. The
discrepancy between these results may be found in the
difference in reporting the gain of IJLI. Whereas in
the Bulgarian study the costs were expressed as those
for one point improvement in UPDRS, in the Lowin
et al. study a more conventional method of cost per
QALY was adapted. Improvement in UPDRS scores
does not necessarily imply an improvement in quality
of life. Moreover, the latter study employed a Markov
model instead of direct real-life data.
In the larger cohorts and in those with longer
follow-up, among others in the United Kingdom, Ger-
many and Ireland, the cost-effectiveness of IJLI was
more favourable. Although Walter & Odin demon-
strated that the incremental costs for IJLI were con-
siderable, with an incremental cost effectiveness ratio
(ICER) of £120,950 (D 165,685) in the UK and
D 188,864 in Germany [24], Lowin et al. showed
much lower costs associated with IJLI treatment.
The latter authors showed that the incremental cost-
effectiveness ratio for IJLI versus standard care was
D 26,944 per QALY (total costs and QALYs for IJLI
and standard care, respectively, were D 537,687 and
D 514,037 and 4.37 vs 3.49), resulting in a cost per
QALY gained of D 26,944 [21], well within the UK’s
GDP at that time (Table 2). The differences in ICER
between the two studies may be explained by the dif-
ferences in temporal horizon which was lifetime for
Lowin et al., and three years for Walter & Odin [22,
24]. It seems unlikely that these differences in cost-
effectiveness was caused by the fact whether a study
was sponsored by a pharmaceutical industry or not.
Both studies received sponsor funding, and also when
extending this to the other included studies, no clear
pattern could be observed between sponsor funded
studies and studies which did not receive such funding
(Table 2).
Kalabina et al. recently confirmed that in the
United Kingdom a considerable incremental gain in
QALYs can be achieved for patients treated with
IJLI of 1.26 QALY with an ICER of £52,110
(D 59,215.91) with a temporal horizon of lifetime use
[26]. Importantly, the authors also showed that, as
advanced stage PD patients often require continuous
care, the QALY gain allowed patients to remain inde-
pendent for longer and, as such, reduce societal and
informal care burden. When this caregiver disutility
was included in the analysis the ICER associated with
IJLI was reduced to £47,266 (D 53,711.36) [26]. In
Sweden, Palhagen et al. looked at the costs associated
with IJLI, although they did not perform a cost-


















Cost-effectiveness of advanced therapies in Parkinson’s disease
Deep brain stimulation
Study Country Type Cost of QALYs Comparator Cost of QALYs Temporal Discount ICER Difference Incremental GDP/capita Cost- Sponsor
of Study Intervention intervention Comparator Comparator Horizon Rate in QALY Cost threshold effectve?∗ bias?
Tomaszewski United CUA $452,000 7.8 BMT $417,000 7.08 Lifetime 3% $49,194 0.72 $35,000 $37,100 Yes Not
and Holloway, States (D 502,222) (D 463,333) (D 54,660) (D 38,889) sponsor
2001 [35] funded
Gerzeli Italy Costs D 20,033 NA BMT D 8,976 NA 1y NA NS NA D 11,057 $28.716 Yes Sponsor
et al., funded
2002 [69]
Meissner Germany CEA D 28,305 NA BMT D 15,991 NA 2 y 5% NS NA D 12,314 $32,237 Yes Not
et al., sponsor
2005 [70] funded
Valldeoriola Spain CUA D 27,614 0.7611 BMT D 20,013 0.5401 1 y NA D 34,389 0.221 D 7,601 $32,429 Yes Not
et al., sponsor
2007 [27] funded
Dams Germany CUA D 133,174 11.62 BMT D 126,180 10.58 Lifetime 3% D 6,677 1.05 D 6,994 $44,994 Yes Not
et al., sponsor
2013 [34] funded
Valldeoriola Spain CEA D 103,730 NA IJLI D 247,918 NA 5 y NS NS NA D –144,188 N/A N/A Sponsor
et al., CSAI D 160,150 NA NA D –56,420 N/A N/A funded
2013 [32]
Eggington United CUA £ 68,970 2.21 BMT £48,243 1.21 5 y 3.5% £20,678 1,002 £20,727 $41,269 Yes Sponsor
et al., Kingdom (D 101,426) (D 70,946) (D 30,409) (D 30,481) funded
2014 [31]
Zhu China CUA $398,110 0.855 BMT $107,258 0.5 2 y 3% $24,868 0.355 $1,347 $13,459 Yes Not
et al., (D 299,331) (D 80,645) (D 18,698) (D 1,013) sponsor
2014 [29] funded
Walter & UK CEA £87,730 2.75 BMT £76,793 2.62 3 years 3.5% NS 0.13 £10,937 $42,522 Yes Sponsor
Odin, (D 120,178) (D 105,196) (D 14,982) funded
2015 [24]
Germany CEA D 105,737 2.85 BMT D 90,012 2.73 3 years 3% NS 0.12 D 15,725 $47,684 Yes
Pietzsch USA CEA $130,510 3.19 BMT $91,026 1.50 10y 3% $23,404 1.69 $19,571 $57,884 Yes Sponsor
et al., (D 117,577) (D 82,005) (D 21,085) (D 17,632) funded
2016 [37]
Fundament UK CEA £73,077 6.69 BMT £46,278 5.35 15y 3,5% £19,887 1.34 £26,799 $44,138 Yes Sponsor
et al., (D 89,118) (D 56,437) (D 24,252) (D 32,682) funded
2016 [28]
Kawamoto Japan CEA $144,600 NS BMT NS NS NS NS NS 6.7 $25,600 $39,990 Yes Not






















Study Country Type Cost of QALYs Comparator Cost of QALYs Temporal Discount ICER Difference Incremental GDP/capita Cost- Sponsor
of Study Intervention intervention Comparator Comparator Horizon Rate in QALY Cost threshold effectve?∗ bias?
Dams Germany CEA D 151,800 13.84 BMT D 115,400 12.25 Lifetime 3% D 22,710 1.59 D 36,400 $50,564 Yes Sponsor
et al., funded
2016 [36]
Vivancos- Spain CEA D 89,477 2.80 IJLI D 234,643 3.12 5 years 3.5% NS –0.32 –D 145,166 N/A N/A Not




McIntosh UK CEA £19,069 0.0286 BMT £9,813 0.0088 1 year 3.5% £468,528 0.02 £9,256 $44,138 Yes Sponsor
et al., (D 23,255) (D 11,967) (D 571,376) (D 11,288) funded
2016 [30]
£113,075 4.66 BMT £71,146 4,06 10 years 3.5% £70,537 0.60 £41,929 $44,138 No
(D 137,896) (D 86,763) (D 86,021) (D 51,133)
Intrajejunal Levodopa Infusion
Kristiansen Sweden CEA SEK 1.48 BMT SEK 1.42 2 years 3% 0.06 SEK SEK $40,187 No Sponsor
et al., 562,000 172,000 390,000 6,100,000 funded
2009 [18] (D 665,213)
Lowin UK CEA £201,192 1.88 BMT £161,548 0.78 Lifetime NS 1.10 £39,644 £36,024 $37,146 No Sponsor
et al., (D 41,407) funded
2011 [22]
Kamusheva Bulgaria CEA BGN 57.42 BMT BGN 22.67 NS NS 34.75 BGN BGN $16,582 Yes Sponsor
et al., 5,655.91 (UPDRS) 143.49 (UPDRS) (UPDRS) 1903.56 158.63 (D 81.45) funded
2013 [16] per point
UPDRS
Lundqvist Norway CEA NOK 0.68 BMT NOK 0.63 1 year NS 0.05 NOK NOK $65,986 No Not
et al., 890,920 419,160 471,760 9,200,000 sponsor
2014 [23] (D 1,180,000) funded
Walter & UK CEA £130,011 3.06 BMT £76,793 2.62 3 years 3.5% 0.44 £53,218 £120,950 $42,522 No Sponsor
Odin, (D 165,685) funded
2015 [24] Germany CEA D 175,004 3.18 BMT D 90,012 2.73 3 years 3% 0.45 D 84,989 D 188,864 $47,684 No




∗review DBS D 89,477 2.80 0.32 D 146,166 $37,310 No
Lowin UK CEA D 537,687 4.37 BMT D 514,037 3.49 Lifetime NS 0.88 D 23,650 D 26,944 $45,998 Yes Sponsor
et al., funded
2017 [21]




































































































































































































































































































































































































































































































































































































































































































































that monthly costs for PD patients on standard thera-
pies compared to those on IJLI was similar (D 8,226),
supporting the feasibility of IJLI [20].
Apomorphine
Unlike IJLI, only three studies have looked at
the cost-effectiveness of continuous subcutaneous
Apomorphine infusion (CSAI) and intermittent
Apomorphine injections. Although not a classical
cost-effectiveness analysis, Heald and colleagues
described the reduction in costs associated with
switching PD patients from oral treatments to
non-oral treatments. They analysed data over a three-
year period in general practitioner practices in the
United Kingdom and found that practices using oral
therapies in PD patients incurred £4,851 (D 6,613)
of secondary care costs in addition to £890 (D 1,213)
primary prescribing costs per weighted patient per
year. In contrast, practices prescribing Apomorphine
incurred £3,954 (D 5,390) per weighted patient,
resulting in a saving of £897 (D 1,223) per year with
an additional cost of £475 (D 648) per patient per
year for prescribing apomorphine [2]. In this study,
it was noted that the costs savings for practices
prescribing intermittent injections was greater than
for those prescribing continuous infusion (£423
vs. £41 per patient per year), and interestingly the
authors showed that prescribing non-oral medication
(apomorphine and rotigotine in this analysis) could
result in a reduction in the annual admission rate for
PD patients of up to 28% [2].
The only true cost-effectiveness studies regarding
CSAI were performed in 2015 in the United Kingdom
and Germany, and in 2016 in Spain. Here, Wal-
ter and Odin described that the direct lifetime costs
of continuous apomorphine infusion was estimated
at £78,251.49 (D 57,123.59) and generated 2.85
QALYs in the United Kingdom, and D 104,500.08
and 2.92 QALYs in Germany (Table 2), showing this
therapy was cost-effective in the UK, but not in Ger-
many [24]. Also Vivancos-Matellano et al. showed
that after five years CSAI was associated with a cost
reduction of D 124,295 compared to IJLI, and a cost
increment of D 20,871 compared to DBS, with an
ICER of D 38,249 per QALY [25], above the GDP
of Spain (Table 2).
Deep brain stimulation
Seventeen articles investigated the cost-effecti-
veness of DBS in PD; nearly all studies compared
DBS to BMT, but two studies compared DBS to
the other device-aided therapies. The sample size
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varied from 29 [27] to 297 [28] patients per study.
A detailed summary of the findings of studies is
included in Table 2.
In the studies with one or two year temporal
horizons the incremental costs ranged between
D 1,013 in a Chinese study [29] to D 11,288 in a study
performed in the UK [30], although not all studies
performed a CEA. In the studies that did provide an
ICER the costs per QALY ranged between D 18,698
and D 571,376 [27, 29, 30]. The wide range between
these studies is not only explained by difference in
prices for DBS between countries, but mainly by the
small gain in QALY between DBS and BMT in the
short term, with difference in QALY being as low as
0.02 [30] (Table 2).
In studies with a three or five year horizons the
ICER for DBS decreases and the differences between
studies becomes less pronounced. Here, it was obs-
erved that the ICER can be as low as D 21,085 in
the UK [24], with the upper limit being at D 30,409
[31] (Table 2). In comparison to the other device-
aided therapies DBS had the most favourable cost-
effectiveness profile [25, 32]. This reduction in costs
after the first few years of DBS implantation was also
noted by others, where it was observed that the costs
of DBS were highest during the first year and included
mainly the costs of the device, surgery and hospi-
talisation, after which they decreased until battery
replacement [33, 34].
In the studies with a temporal horizon of 10 years
or more (up to life-time), the tendency for decreasing
costs associated with DBS becomes clearer. Here, for
example, Tomaszewski et al. showed that total life-
time costs were $452,000 for STN DBS and $417,000
for BMT. QALYs gained were 7.80 and 7.08, respec-
tively, resulting in an ICER of $49,194 (D 54,660)
[35]. Compared to the results of Dams et al. both
costs and utilities were high, as in the latter study the
ICER was only D 6,677 [34]. Incremental costs, how-
ever, were similar and it should be noted the studies
were performed 12 years apart [36].
A similar low ICER was noted in the studies by
Pietzsch et al. and Fundament and colleagues [28,
37], yet could not be confirmed in a UK based study
were the ICER was D 86,021 due to the only modest
QALY gain of 0.60 of DBS compared to BMT [30]
(Table 2). Interestingly, even in PD patients with early
stage disease the ICER of STN DBS can be relatively
low at D 22,710 [36].
The discrepancy between the included DBS stud-
ies can result from differences in the context-specific
costs and utility calculations, however all included
studies showed that DBS is cost-effective. Additi-
onally, differences between studies in terms of par-
ticipants’ severity of PD and the duration of motor
fluctuations may have had an impact on direct costs
[38, 39]. This was also demonstrated by Espey et
al. who compared early vs late DBS and reported
2.5 additional QALYs for early initiation of DBS.
Assuming a lifelong time horizon for cost-effec-
tiveness calculations this may have resulted in a ben-
efit compared to studies that employed a relatively
later initiation of DBS [40].
Comparison of the three advanced therapies
Three studies have compared the advanced the-
rapies for PD in terms of cost-effectiveness. Vallde-
oriola et al. have compared all three therapies and
found that the mean cumulative five-year cost per
patient was lowest in patients treated with DBS
(D 88,014), and highest in those on IJLI (D 233,986)
(costs associated with apomorphine infusion were
D 141,393). Despite initial high costs associated with
DBS (32.3% of the total five-year costs for this
therapy), yearly average started decreasing in the sec-
ond year post-intervention with costs of D 17,603,
compared to D 46,797 for IJLI and D 28,279 for apo-
morphine infusion [32].
In the PND27 Study, performed in the United
Kingdom, it was estimated that the discounted costs
over five years were £69,566 and £80,843 for DBS
and apomorphine infusion, respectively, resulting in
a cost savings of £11,277 for DBS. In this study
cost savings for DBS started from the third year post-
intervention, with the initial costs of implantation of
the DBS device offset by the ongoing need for apo-
morphine drug provision [41]. Finally, as mentioned
before, Vivancos-Matellano and colleagues showed
that CSAI was associated with a 5-year cost reduction
of D 124,295 compared to IJLI, and a cost increment
of D 20,871 compared to DBS [25] (Table 2).
Device-aided therapy cost reduction efforts
As evidenced in Table 2 most studies with a tem-
poral horizon of five years or over show that the
ICER for the three device-aided was less than or only
slightly above the GDP for the countries where the
respective studies were conducted. As such, it may
be concluded that most device-aided therapies are
or have the potential to be, in the long-term, cost-
effective, although this is more clear for DBS than for
the infusion therapies. In order to further reduce the
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costs associated with device aided therapies, specifi-
cally the infusion therapies, several efforts have been
undertaken.
For DBS, rechargeable implantable pulse genera-
tors (IPGs) are currently the most promising effort
to reduce costs and can also influence higher patient
satisfaction associated with reduction of the burden
of frequent recharging. Cost analyses revealed that
the estimated reduction of costs are approximately
D 1,000–2,000 per patient per year over the lifespan
of the rechargeable IPG (estimated at 9 years for the
Activa RC) [42, 43].
One of the most promising strategies to reduce
costs associated with LCIG is the introduction of
catechol-O-methyltransferase (COMT) inhibition ei-
ther added to the LCIG infusion suspension, or as an
add-on therapy. By adding Entacapone to the LCIG
suspension (LECIG), Senek et al. were able to show
that the Levodopa dose for some patients could be
decreased by more than 20%, e.g., by decreasing
maintenance dose flowrate while treatment response
scores did not change [44]. This LECIG combination
is now being marketed in some northern European
countries with a price identical to LCIG (around
D 155) [45]. Similarly, by adding oral Opicapone,
a new third-generation COMT inhibitor, in patients
on LCIG a reduction of 24.8% in LCIG daily dose
could be achieved, without changes in motor perfor-
mance, including stable dyskinesia levels. Moreover,
a theoretical net average cost savings of £21,497.88
(D 24,518.33) per patient per year could be achieved
[46]. Even though these strategies need to be explored
further, they offer hope that the high costs of LCIG
and the associated costs per QALY currently over
the GDP threshold could be reduced. To our knowl-
edge, there are no strategies underway to reduce CSAI
costs.
Other factors that should be taken into account
when discussing the potential of cost reduction, are
caregiver burden and other medical costs, as improve-
ments in these factors are likely to further reduce
the costs associated with device-aided therapies. As
shown in studies for LCIG, taking into account care-
giver disutility the costs per QALY could be reduced
by almost 10% [26]. In addition, general practitioner
practices in the UK prescribing device-aided thera-
pies (apomorphine) are capable of monthly savings
on other healthcare costs and up to a 28% reduction
in the annual admission rate for PD patients [2].
Other factors to take into account, are indirect costs
which include lost productivity (e.g., the costs due
to premature retirement, reduction of working hours,
and sick and disability leave) and formal and infor-
mal care (e.g., unpaid help from others for everyday
activities) [47]. The latter has been demonstrated to
be the greatest component of societal and family bur-
den associated with 5% of total costs of which 80%
are the costs related to informal care [48]. Other
cost-driving factors that have been reported across
several countries include premature retirement [39].
Indirect costs associated with premature retirement
in PD ranged from D 860 (95% CI: D 630–D 1090)
in Russia to D 3,910 (95% CI: D 2,510–D 6,140) in
Austria and accounted for 30–68% of all PD costs.
However, such indirect costs are rarely and incom-
pletely reported in cost analysis studies [39, 47]. If
device-aided therapies are able to improve these fac-
tors, and thereby reduce indirect costs, this will make
them more cost-effective in the long term.
DISCUSSION
Based on the available evidence all three device-
aided therapies in PD, DBS, CSAI and IJLI, are able
to improve quality of life compared to best medi-
cal treatment with oral therapies, with improvements
between 0.88 and 1.26 QALY in the studies with
long temporal horizons. This improvement appears
to be more pronounced for IJLI than CSAI and
DBS, although studies directly comparing these three
device-aided therapies are few. Nonetheless, these
improvements in quality of life are substantial and
certainly merit serious consideration in view of the
prevailing cost-effectiveness criteria. Based on the
criteria used in the current review we have shown
that DBS is a cost-effective device-aided treatment
for PD, but this picture is less uniform for the infusion
therapies.
Whether or not therapies are deemed cost-effective
often depends on health authority regulations in indi-
vidual countries. In the UK, where many of the in-
cluded studies in this review were performed, the
National institute for Health and Care excellence
(NICE) will often only appraise a technology or new
medication if the ICER is less than £20,000 per
QALY gained, and it is unlikely to approve interven-
tions with an ICER of £30,000 or over per QALY
gained. Exceptions are made if a therapy has a very
clear treatment effect and offers additional effects
beyond standard therapy [49]. However, this situ-
ation is not uniform and the ‘willingness to pay’
per QALY differs vastly across countries [50]. In
2018, the range of costs per QALY for diseases
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in general that different European countries were
willing to pay ranged from $19,006 (D 16,107) in
Poland to $180,653 (D 153,096) in Belgium [50],
although these numbers do not need necessarily
apply to PD. As such, it is unlikely that all device-
aided therapies will be approved in every country
in Europe, mainly IJLI which is the most expen-
sive device-aided therapy. Although fixed criteria to
assess whether an intervention is cost-effective are
lacking and differ from country to country, some
studies have proposed, e.g., the one by Laupacis et
al., that treatment was considered cost-effective if
the costs were below D 50,000/QALY [51]. Other
approaches, including the one we deployed in the
current review, suggest that the ICER should be
below the gross domestic product (GDP) of a coun-
try per capita [16]. GDP as a benchmark to evaluate
cost-effectiveness of a therapy has been promoted
by the World Health Organization’s Choosing Inter-
ventions that are Cost–Effective (WHO-CHOICE)
project [52]. However, it has been also argued that
the thresholds based on per capita GDP had major
shortcomings and should be abandoned as guides
for policy-makers [53]. Thus, the appropriate mea-
sure and threshold of cost-effectiveness remains
controversial and there are still no established and
commonly accepted criteria. Furthermore, it is a
commonplace that therapies that are considered suf-
ficiently promising and therefore get funded often
develop (due to scientific and technological progress)
and become more cost effective over time [54]. That
is why it may be reasonable to fund some particu-
larly beneficial therapies even despite their relative
low cost-effectiveness rate. Practical applicability of
a therapy may create an incentive to develop it fur-
ther to become more cost-effective, while its rejection
due to insufficient cost-effectiveness (irrespective of
its medical effects) usually impairs its potential for
improvement, including cost-benefit ratios. It entails
that even a relatively low cost-effectiveness of a
therapy may, at least in some cases, be compen-
sated by strictly medical effectiveness accompanied
by a potential for further technological development
reducing its costs.
In addition to the ICER for the three device-aided
therapies being within the ‘willingness-to-pay’ lim-
its per QALY for most countries for which such
data is available, the introduction of these therapies
in the complicated stages of PD may have further
benefits. Although not usually included in the cost-
effectiveness analyses as an outcome, some authors
have suggested that cost savings might be achieved
by a reduction in care giver burden and indirect costs
associated with care. For example, Heald and col-
leagues demonstrated that in the UK the prescription
of non-oral medication (apomorphine and rotigotine
in this study) resulted in a reduced annual admission
rate of up to 28% [2]. In this respect, it is inter-
esting to note that Findley et al. found that cost of
care for patients with advanced PD, calculated as
direct non-medical and indirect costs, accounted for
over 85% of total costs [55]. More specifically, the
authors observed that direct non-medical costs of pro-
fessional care in the UK accounted for 50% of costs,
indirect informal care 43%, whereas only 7% of total
costs could be attributed to directly incurring medical
costs. The latter was determined mostly by hospi-
talisation, followed by health professional visits and
testing. In addition, when a caregiver is considered in
cost-effectiveness analyses, one study looking at IJLI
has shown that the gain in QALYs allows patients to
remain independent for longer and, thereby, reduce
societal and informal care burden. In terms of costs,
this resulted in an additional D 5,500 reduction in
ICER [26].
Interestingly, most cost-effectiveness analyses in
device-aided therapies have focused on the impro-
vement of motor function as a driver for the improve-
ment in quality of life and QALYs. Non-motor
symptoms, however, have an at least equal, if not
more important contribution to quality of life in PD
[56]. Future analyses should include improvements of
non-motor symptoms in their analyses as it is known
that all device-aided therapies improve non-motor
burden and have a differential effect on the spectrum
of non-motor symptoms that improve, along with
an associated improvement in quality of life [9, 10,
12, 57]. In addition, indirect costs, such as a reduc-
tion in caregiver burden and reduced medical care
costs, among others related to a reduction in hospi-
tal admissions, should be taken into account in future
studies.
At first glance, when comparing the three device-
aided therapies, DBS appears to be the most cost-
effective therapies. However, certain limitations to
this conclusion should be acknowledged. First and
foremost, it should be realised that the patients that
receive DBS, compared to those selected for infusion
therapies, show certain differences in demographic
characteristics. Patients selected for DBS are often
younger and with a shorter disease duration than those
selected for CSAI, and especially IJLI [9, 10], and
per DBS protocols patients with cognitive decline
or depression are not selected for DBS [58]. These
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latter restrictions are less stringent for the infusion
therapies. As all these factors contribute to quality of
life, both through increasing motor and non-motor
burden with increasing age and disease duration,
the improvements observed on quality of life after
introduction of these therapies is unlikely to be com-
parable across groups. Additionally, and unlike the
case for IJLI and CSAI, Dams et al. reported that DBS
can be efficiently applied at an earlier stage of disease
[36], as also recommended in guidelines. Despite the
consistent observations that DBS is more costly then
oral treatment, expenses can be justified by the gain
in health advantages. The authors demonstrated that
DBS can be applied in early stages of PD for a gener-
ally acceptable price of D 22,700/QALY gained [36].
Choosing which device-aided treatment option is
most suitable is not just a question of health eco-
nomics, but requires a careful process, in which the
patient’s and carers’ preferences and the clinician’s
expertise contribute equally to the decision. Nonethe-
less, the implementation of device-aided therapies
in PD appears to be challenging and during this
process one is regularly confronted with imple-
mentation barriers occurring in clinical practice
[59]. First of all, even though PD patients need
to be involved in a shared-decision making pro-
cess, they often feel ill-equipped and unsupported
by medical specialists, although this is country and
healthcare system specific and need not apply to
all situations [60]. Furthermore, selecting eligible
patients for advanced therapies often appears to be
a challenging task in clinical practice. The selec-
tion for all device-aided therapies in PD should
carefully assess the following factors: disease dura-
tion, age, levodopa responsiveness, type and severity
of levodopa-unresponsive symptoms, cognitive and
psychiatric issues, comorbid disorders, and for DBS
also brain magnetic resonance imaging (MRI) find-
ings [61]. Moreover, neurologists regularly mention
limited decision-making capabilities in PD patients
as an additional barrier in patients with advanced PD,
where increasing disease severity and associated cog-
nitive deficits further complicate these capabilities
[62]. Other factors of influence include the patient’s
place of residence, where, for example, patients in
rural areas often have limited access to specialised
centres providing device-aided therapies for PD [63].
This may lead to delayed referral and delayed con-
sideration for non-oral treatments, causing a general
under-treatment of advanced PD [60]. Related to this,
patients are often first seen by a general neurologist,
who may not have specialised knowledge regarding
advanced treatments in PD, further influenced by the
lack of access to multidisciplinary team care and lack
Table 3
Barriers for the implementation of advanced therapies in Parkinson’s disease
Barrier Reference
Direct barriers
Limited number of randomised trials directly comparing advanced [64]
treatments to guide treatment decision
Various patients are considered too late for advanced therapies, [65]
leading to general under-treatment of advanced PD
Limited expertise among clinicians due to a lack of treatment [72]
experience or availability of advanced treatments
PD patients are involved in the decision-making processes; [59, 60]
however, they often feel ill-equipped and unsupported
by the medical specialists. Neurologists mention limited
decision-making capacity in PD patients as an additional
barrier to SDM in advanced PD, related to disease severity,
and associated cognitive deficits
Treatment complications of advanced therapies, including [73, 74]
increased risk of falling or development of hallucinations
Other potential barriers
Pre-intervention: [65]
• Appropriate patient selection
• Management by an experienced Movement disorders service
During intervention [65]
• Inpatient versus outpatient model
Post-intervention [65]
• Structured daily routine
• Support from partner
• Support from health care professionals at home
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of experience with device-aided therapies and their
beneficial effects [64]. Finally, from both a patient’s
and health care professional’s perspective, potential
post-interventional adverse events might represent
an additional barrier in choosing device-aided thera-
pies (Table 3). Examples include the greater risk of
falling and hallucinations in DBS, potentially leading
to longer hospitalization, local nodules at infection
site, haemolytic anaemia, fatigue, dizziness, ortho-
static hypotension, and electrocardiographic changes
in CSAI [65, 66], and the development of polyneu-
ropathy in IJLI treated patients [67]. Related to this,
there is limited unbiased and comparable informa-
tion for all three options, as no randomized controlled
trials directly comparing the device-aided therapies
have been conducted [59]. However, trials with such
comparisons are underway and the results are awaited
with great interest [68].
CONCLUSIONS
In summary, of the device-aided therapies DBS is
clearly cost-effective, as these costs are around or
below the GDP of the countries where the studies
looking at this have been performed. For the infusion
therapies this picture is less uniform, although current
studies seem to support that long-term use of these lat-
ter therapies favours their cost-effectiveness profile.
Nonetheless, universally acceptable cost thresholds
for device-aided therapies are lacking. Additionally,
often indirect, improvement of factors other than
motor improvement used as the primary endpoint
to determine effectiveness, may justify the use of
infusion therapies in PD. Moreover, several studies
regarding cost-effectiveness for device-aided thera-
pies in PD with a temporal window of over five
years show that the ICER was within, or at least near,
the respective countries’ GDP per capita, the thresh-
old that remains the prevailing measure of assessing
cost-effectiveness for public policy decisions. This
suggests that further improvement to the delivery
of infusion therapies is likely to make them cost-
effective in the long-run. Several studies suggest that
societal costs and costs associated with care burden
with these therapies and other indirect costs, often
not taken into account in cost-effectiveness analyses,
decrease compared to best medical therapy. Although
DBS appears to be the most cost-effective of the three
device-aided therapies, caution should be observed
when comparing to the infusion therapies. Often
the PD patient populations for DBS and infusion
therapies differ, as e.g., per DBS inclusion criteria
patients with cognitive problems or depression are
excluded, but are often, to a certain extent, allowed
for patients on infusion therapies. In addition to the
recent efforts that have been made to reduce the direct
costs of the infusion therapies, other factors need to
be taken into account. As most analyses performed to
date have only looked at the effectiveness based on
motor improvement, future cost-effectiveness anal-
yses should additionally look at non-motor effects
and associated improvements in quality of life and
reductions in both direct and indirect costs.
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